NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

Halozyme Therapeutics, Inc. (HALO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HALO

$110.19

−$0.57 (−0.51%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HALO with… →

HALO Key Statistics

As of Sep 4, 2026
Trading
Open
$109.91
Previous Close
$110.76
Day's Range
109.00–111.15
52-Week Range
61.23–111.15
Volume
1.01M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$12.51B
P/E Ratio
32.31
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.60
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.52
EPS (ttm)Profit attributable to each share over the last twelve months.
3.41
Financials (FY)
Revenue (FY)
$1.40B+37.55%
Net Income (FY)
$316.89M−28.64%
Profit marginThe share of revenue left as profit after all costs and taxes.
24.86%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
113.50M
1-Year Return
+50.12%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
1.98M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HALO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+63.73%
2025+40.77%
2024+29.36%
2023−35.04%
2022+41.51%
2021−5.85%
2020+140.89%
2019+21.19%
2018−27.79%
2017+105.06%
2016 (partial year)−2.08%

As of September 4, 2026.

HALO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.40B$316.89M22.7%
2024$1.02B$444.09M43.7%
2023$829.25M$281.59M34.0%
2022$660.12M$202.13M30.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.40B$1.17B$802.59M$316.89M22.7%
2024$1.02B$855.91M$551.48M$444.09M43.7%
2023$829.25M$636.89M$337.57M$281.59M34.0%
2022$660.12M$520.81M$267.53M$202.13M30.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HALO Valuation vs Biotechnology Median

Median of 656 stocks
MetricHALOBiotechnology medianvs median
P/E32.3112.57157% above
P/S ratio7.5215.2651% below
Profit margin24.86%0.00%24.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Halozyme Therapeutics, Inc. (HALO) at $12.51B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 423.

Over the past 52 weeks the price has ranged from $61.23 to $111.15. The most recent close on file for HALO is $110.19, dated September 4, 2026. That is −$0.57 (−0.51%) against the previous close. The latest close sits 79.96% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.40B. Against the prior fiscal year total of $1.02B, that is a change of +37.55%. The same year closed with net income of $316.89M. That is −28.64% against the prior fiscal year. The reported profit margin is 24.86%. That is 24.9 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 3.41.

Across the 4 fiscal years on file, revenue moves from $660.12M in 2022 to $1.40B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 32.31. That is 157.04% above the Biotechnology median of 12.57. The forward P/E on file is 10.6. The price-to-sales ratio is 7.52. On price-to-sales that is 50.75% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.88. Daily returns over the trailing 10 years annualize to a volatility of 42.76%. Over the trailing twelve months the price has returned +50.12%. Across 10 years the annualized return works out at +27.31%.

Growth & Income

No dividend is on file for HALO.

The strongest complete calendar year on file is 2020 at +140.89%; the weakest is 2023 at −35.04%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +63.73% year to date.

Peer Comparison

Halozyme Therapeutics, Inc. (HALO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Halozyme Therapeutics, Inc. HALO $12.51B 32.3
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Halozyme Therapeutics, Inc. trades at a P/E of 32.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Visit website →